Share Name Share Symbol Market Type Share ISIN Share Description
Cvs Group Plc LSE:CVSG London Ordinary Share GB00B2863827 ORD 0.2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 1,241.00 1,239.00 1,242.00 - 0.00 01:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
General Retailers 427.8 9.9 8.1 153.2 877

Cvs Share Discussion Threads

Showing 626 to 645 of 650 messages
Chat Pages: 26  25  24  23  22  21  20  19  18  17  16  15  Older
Volume stimulated by news. share price has been relatively stable since the July update and sept results. Good time to be adding regularly.
Volume seems to be drying up. Can sometimes be the predecessor to a big surge which moves the price (hopefully upwards).
Lots to like with an excellent update on the first two months. Anecdotally the vets are very busy, they are operating safely and profitably. IMHO this is looking like a much stronger business. I expect there will be a number of small practices that will want to sell up and CVSG will be paying less to acquire them. One to believe in again.
Outlook Through the actions taken during the COVID-19 pandemic, and the support and professionalism of our colleagues, CVS is well positioned to withstand any future Brexit or COVID-19 disruption and deliver future growth. We saw a continuing strong recovery from the close of the last financial year, which was faster than expected to reach pre COVID-19 levels. Trading for the first two months of this year are ahead of budget and up 3.5% on the prior year, with LFL sales similarly up 3.9%. Adjusted EBITDA was also comfortably ahead of that seen in the prior year (+6.4%). This primarily reflects continued clinical care and increased referrals. Cash generation remained strong in the first two months and leverage further reduced to 0.8x creating a further buffer against business disruption and the ability to invest in future growth. I look forward to delivering our new strategy and sharing further success in the future. Richard Fairman Chief Executive Officer 24 September 2020
Dividends Having taken advantage of government support during the COVID-19 pandemic, and in line with the approach taken by many other companies, the Board does not intend to recommend the payment of a final dividend. Shareholder engagement Prior to COVID-19, the Directors regularly held one-to-one meetings and calls with shareholders. Although the Directors temporarily suspended issuing guidance due to COVID-19, we continue our regular interactions with shareholders. Outlook CVS operates in a sector with favourable market and consumer trends, with pet owners who remain willing to spend money on their pets and medical enhancements increasing the range of services we can offer. COVID-19 severely impacted our business in the last quarter of this financial year, reducing our revenues. CVS was eligible for, and successfully accessed, the Coronavirus Job Retention Scheme and placed over half of all employees on furlough. CVS also accessed support from taxation authorities in the UK and the Netherlands. I am pleased to say that post year-end, all of our employees have now returned from furlough leave. As described more fully in the CEO's statement, trading in the first two months has been encouraging. Despite continued uncertainty over Brexit, I am confident that CVS is well positioned to avoid significant adverse impacts from the UK's decision to exit the EU. Pharmaceutical manufacturers and wholesalers are increasing their stock levels in order to reduce the risk of supply shortages and, following the acquisition of Vet Direct in 2018, CVS now controls more directly its equipment and consumables supplies. Looking ahead, we welcome the positive environment for acquisitions and are well placed to take advantage of growth opportunities. The pace of growth in the UK economy may be impacted by Brexit and COVID-19 uncertainty, but the veterinary sector has proven to be resilient in past periods of economic downturn and the Board believes that CVS is well-positioned to withstand any potential future downturn. Richard Connell Chairman 24 September 2020
What a difference a new management team can make, with greater focus on the business rather than a manic acquisition strategy. One of Investor's Champion's favourites reflected in the latest update
Solid set of results, given the impact of COVID, encouraging start to the new financial year bodes well.
Https:// (Investors Chronicle) Britain’s largest veterinary-services company operates more than 500 practices. Levels of pet ownership have risen steadily over the last ten years and “rocketed” under lockdown. The number of insured pets has risen too, which will “help to protect CVS’s income in an economic downturn”. The reopening of its small-animal sites has boosted sales. The forward price/earnings ratio of 23 does not fully reflect the company’s potential. 1,205p
Final dividend Having taken advantage of government support, and in line with the approach taken by many other companies, the Board does not intend to recommend the payment of a final dividend. Outlook: post COVID-19 lockdown Since April 2020 CVS have, where possible, reopened practices and un-furloughed employees. We are pleased that by the financial year end the majority of our practices were open and the majority of employees have returned to work. The Board is confident that the actions taken have been in the best interest of both our employees and our clients and have not had a detrimental impact on the number of active clients that the Group services. Alongside the re-opening of our practices, we have taken the decision to permanently close 33 sites in the Group, the majority of which are small branches of larger practice groups which were either marginal or loss-making. The Board is confident that the majority of clients formerly served by these sites will continue to be served by our larger and better equipped CVS veterinary sites close by. CVS is a diversified business with strong coverage in the UK and an established platform in the Republic of Ireland and the Netherlands. The Group provides an essential service to companion animals and supports the maintenance of the food supply chain. We continue to maintain 415,000 Healthy Pet Club subscription memberships which provide recurring revenue and which continue to be a resilient source of cashflow. Animed Direct, our online pharmacy and retail business, has performed well throughout the financial year and has benefitted from an increase in demand during the lockdown period. Leverage has materially reduced from the 1.61x reported at the end of February 2020 due to the actions taken by the Board to both protect the business and preserve cash (30 June 2019: 2.08x). The Company continues to refrain from giving guidance to analysts. Whilst there is ongoing COVID-19 uncertainty with the potential risk of further future lockdowns, the Board is confident that the business is robustly managed and well positioned to drive further increases in shareholder value.
Peel Hunt Buy 1,130.00 - Reiterates
Upcoming events on CVS GROUP PLC JULY/24/2020 FY 2020 Sales and Revenue Release - Trading Update
Strong resistence it seems at 1019p Https://
Read more in our update of announcements here: Https://
Berenberg Buy UP FROM 1,200.00 TO 1,400.00 Reiterates
RNS Number : 2678C CVS Group plc 07 February 2020 7 February 2020 CVS Group plc ("CVS" or the "Company" and, together with its subsidiaries, the "Group") Trading Update CVS, one of the UK's leading providers of integrated veterinary services, provides the following update on headline trading in respect of the financial half year ended 31 December 2019 ("H1 2020"). The Company will announce its interim results, for the six months ended 31 December 2019, on 27 March 2020. Overview The Board is pleased to announce that the improved trading performance delivered in the second half of the financial year to 30 June 2019, and the encouraging start to the new financial year, as announced at the time of our Annual General Meeting on 28 November 2019, has continued for the remainder of the half year to 31 December 2019. H1 2020 Performance In H1 2020, the Group's total sales increased by 15.0% and like-for-like sales(1) ("LFL") increased by 8.4%, in each case compared to the financial half year ended 31 December 2018 (H1 2019). Within the Group's core Practice division, total sales increased by 13.7% and Practices LFL(2) sales increased by 7.4%, in each case compared to H1 2019. Gross margins(3) for the Group in H1 2020 were 76.0% compared to 76.2% in H1 2019. This slight reduction primarily results from strong sales growth for Animed Direct, our online dispensary, for which margins are lower and which accounted for 6.3% of Group sales in H1 2020 (H1 2019: 5.3%). Practice division gross margins improved to 78.3% in H1 2020 from 77.8% in H1 2019. Within the Practice division, the growth in total and LFL sales and the improvement in gross margin largely reflect the continuing focus on high quality clinical work, including increased volume and value of referrals within the Group, and the benefit of modest price increases previously described in our November 2019 update. Employment costs for the Group in H1 2020 were 51.0% of total sales, compared to 51.6% in H1 2019. This reduction stems from a continued focus on the retention of clinical staff and the Group is pleased to announce that its veterinary surgeon vacancy rate averaged 7.8% in H1 2020 (H1 2019: 8.7%). As a result of the above, CVS expects to report H1 2020 Adjusted EBITDA(4) that is materially above that delivered in H1 2019. This is in line with management expectations and is attributed to the better performance in H1 2020 as well as the weaker comparative in H1 2019. Outlook As previously stated, the comparatives become more challenging in the second half of the current financial year, given the improved performance seen in H2 2019. The continuing positive trends in key performance indicators provide further assurance that the Group is trading in line with management's expectations for the full year.
Giulia Bottaro 08:04 Fri 07 Feb 2020 viewCVS Group CVS Group on the mend as vet shortage eases The vet group has recovered since last year's profit warning due to a shortage of vets CVS Group - CVS Group continues to improve trading CVS Group PLC (LON:CVSG) has bounced back from a profit warning a year ago sparked by a shortage of vets, which pushed up staffing costs. The AIM-listed pet care firm expects underlying earnings (EBITDA) this year to be “materially ahead” of the previous year helped by easier comparatives. In the six months to 31 December, like-for-like sales rose 8% while total sales were up 15% over the half-year. Gross margins dipped by 0.2% to 76% due to higher revenue from the low-margin online dispensary segment though employment costs as a percentage of sales eased slightly to 51%. Net debt narrowed 5% to £97mln. Add related topics to MyProactive
I believe the thesis. Although I don't see this as completely bulletproof, I like the steps management have taken. Long-term looks fine, near term depends. Brexit didn't help, but if homebuilders are on their way up I don't see why vet services shouldn't participate in the market as well.
lovely looking chart but I must check fundamentals to see if it appears to be overbought ! anyone any thought on that please ?
CVS Group PLC CVSG Peel Hunt Buy 1,150.00 - Reiterates
A big reason why Innes sold one third of his shares would be taxation. As an employee of CVS his shares are treated as a business for CGT and taxed at 10% on gains. After he has left CVS in the next few weeks he would be taxed like everyone else at 40%.
magnum opus
Chat Pages: 26  25  24  23  22  21  20  19  18  17  16  15  Older
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20201022 07:13:02